Compare Heron Therapeutics Inc (HRTX) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while YieldMax MSTR Option Income Strategy ETF trades at $15.7 (market cap $1.11B). The key difference: YieldMax MSTR Option Income Strategy ETF is far larger — about 15× Heron Therapeutics Inc's market cap, and YieldMax MSTR Option Income Strategy ETF is more actively traded (3,805,384 versus 3,668,095). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and YieldMax MSTR Option Income Strategy ETF for 30 Days on average.
| HRTX | MSTY | |
|---|---|---|
Market Cap | $74.04M | $1.11B |
Volume | 3,668,095 | 3,805,384 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.49 | $67.85 |
52-Week Low | $0.27 | $11.55 |
Typical Hold Time | 35 Days | 30 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
MSTY, the YieldMax MSTR Option Income Strategy ETF, trades at $15.83, down 5.61% with a bearish technical signal. The fund generates weekly distributions through options strategies on MicroStrategy stock, with recent payouts ranging from $0.16 to $0.34. Despite high distribution rates exceeding 100% annualized, the fund has experienced significant NAV erosion, declining approximately 34% over six months according to 24/7 Wall Street analysis from July 2026.
The outlook remains challenging as MSTY's strategy sacrifices capital appreciation for income generation. While the high distribution rate provides income, the structural erosion of NAV presents substantial risk. Investors face the dual challenge of receiving taxable distributions while experiencing principal decline, making this suitable only for those prioritizing current income over capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
